Search
BioCardia Inc
BCDAAdd to Watchlist
1.220USD
-0.020-1.61%
Market hours （ET）Quotes delayed by 15 min
13.12MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of BioCardia Inc is 8.00, ranking 165 out of 387 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 25.00 and a low of 6.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
15.500
Target Price
+1180.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
BioCardia Inc
BCDA
2
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BioCardia Inc's price target?
Analysts forecast that BioCardia Inc's price target is USD 15.50, with the highest forecast at USD 25.00 and the lowest forecast at USD 6.00.
How have BioCardia IncBCDA's recent earnings per share performed?
The market expectation was USD -0.21, while BioCardia IncBCDA's earnings per share (EPS) for the previous quarter was USD -0.19. EPS for the next quarter is expected at USD -0.18.
What is the analyst rating for BioCardia Inc?
Based on the ratings of BioCardia Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.